Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hans Peter Hartung

Showing results (21-30 of 601) with videos related to

Pageof 61
Sort By:
Journal of Neurology|July 21, 2004
Assessment and management of neutralizing antibodies in patients with multiple sclerosisHans-Peter Hartung, Frederick E Munschauer
Trends in Neurosciences|January 5, 2010
Neuroprotection, regeneration and immunomodulation: broadening the therapeutic repertoire in multiple sclerosisOrhan Aktas, Bernd Kieseier, Hans-Peter Hartung
Trends in Pharmacological Sciences|June 25, 2013
Polyclonal immunoglobulin G for autoimmune demyelinating nervous system disordersMathias Buttmann, Srini Kaveri, Hans-Peter Hartung
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|December 25, 2015
Advances in and Algorithms for the Treatment of Relapsing-Remitting Multiple SclerosisJens Ingwersen, Orhan Aktas, Hans-Peter Hartung
Trends in Pharmacological Sciences|October 27, 2015
PML: The Dark Side of Immunotherapy in Multiple SclerosisClemens Warnke, Tomas Olsson, Hans-Peter Hartung
Nature Reviews. Neuroscience|April 2, 2005
Statins--a cure-all for the brain?Til Menge, Hans-Peter Hartung, Olaf Stüve
Current Opinion in Neurology|April 2, 2016
Optic neuritis as a phase 2 paradigm for neuroprotection therapies of multiple sclerosis: update on current trials and perspectivesOrhan Aktas, Philipp Albrecht, Hans-Peter Hartung
Neurology(R) Neuroimmunology & Neuroinflammation|March 3, 2021
Neuroprotective Properties of 4-AminopyridineMichael Dietrich, Hans-Peter Hartung, Philipp Albrecht
Current Opinion in Neurology|April 9, 2016
Steering through complexity: management approaches in multiple sclerosisBruce A C Cree, Hans-Peter Hartung
Journal of Neurology|January 6, 2019
Long-term follow-up of multiple sclerosis studies and outcomes from early treatment of clinically isolated syndrome in the BENEFIT 11 studyHans-Peter Hartung, Jonas Graf, David Kremer
Pageof 61

Showing results (21-30 of 601) with videos related to

Sort By:
Pageof 61
Journal of Neurology|July 21, 2004
Assessment and management of neutralizing antibodies in patients with multiple sclerosisHans-Peter Hartung, Frederick E Munschauer
Trends in Neurosciences|January 5, 2010
Neuroprotection, regeneration and immunomodulation: broadening the therapeutic repertoire in multiple sclerosisOrhan Aktas, Bernd Kieseier, Hans-Peter Hartung
Trends in Pharmacological Sciences|June 25, 2013
Polyclonal immunoglobulin G for autoimmune demyelinating nervous system disordersMathias Buttmann, Srini Kaveri, Hans-Peter Hartung
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|December 25, 2015
Advances in and Algorithms for the Treatment of Relapsing-Remitting Multiple SclerosisJens Ingwersen, Orhan Aktas, Hans-Peter Hartung
Trends in Pharmacological Sciences|October 27, 2015
PML: The Dark Side of Immunotherapy in Multiple SclerosisClemens Warnke, Tomas Olsson, Hans-Peter Hartung
Nature Reviews. Neuroscience|April 2, 2005
Statins--a cure-all for the brain?Til Menge, Hans-Peter Hartung, Olaf Stüve
Current Opinion in Neurology|April 2, 2016
Optic neuritis as a phase 2 paradigm for neuroprotection therapies of multiple sclerosis: update on current trials and perspectivesOrhan Aktas, Philipp Albrecht, Hans-Peter Hartung
Neurology(R) Neuroimmunology & Neuroinflammation|March 3, 2021
Neuroprotective Properties of 4-AminopyridineMichael Dietrich, Hans-Peter Hartung, Philipp Albrecht
Current Opinion in Neurology|April 9, 2016
Steering through complexity: management approaches in multiple sclerosisBruce A C Cree, Hans-Peter Hartung
Journal of Neurology|January 6, 2019
Long-term follow-up of multiple sclerosis studies and outcomes from early treatment of clinically isolated syndrome in the BENEFIT 11 studyHans-Peter Hartung, Jonas Graf, David Kremer
Pageof 61